Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: Clinical, radiological, and molecular features

Neuro-Oncology

Volumn 14, Issue 8, 2012, Pages 1090-1096

  Goutagny, Stéphane ^a,b,d   Bah, Alpha Boubacar ^a   Henin, Dominique ^b,c   Parfait, Béatrice ^a   Grayeli, Alexis Bozorg ^a   Sterkers, Olivier ^a,b   Kalamarides, Michel ^a,b,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BEAUJON HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

^d INSERM   (France)

Author keywords

meningioma; natural history; neurofibromatosis; volume

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN EDEMA; CANCER GRADING; CANCER GROWTH; CANCER SURGERY; CHILD; CHROMOSOMAL INSTABILITY; CHROMOSOME 18Q; CHROMOSOME 1P; CHROMOSOME 22Q; CHROMOSOME 6P; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEUROFIBROMATOSIS 2; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84864721953     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos129     Document Type: Article

References (27)

1. Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A:327-332.
2. Asthagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. Lancet. 2009;373:1974-1986.
3. Smith MJ, Higgs JE, Bowers NL, et al. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutation: Clear positional effect of mutations, absence of female severity effect on age at onset. J Med Genet. 2011;48(4):261-265.
4. Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med. 1992;84:603-618.
5. Parry DM, Eldridge R, Kaiser-Kupfer MI, et al. Neurofibromatosis 2 (NF2): Clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994;52:450-461.
6. Otsuka G, Saito K, Nagatani T, et al. Age at symptom onset and longterm survival in patients with neurofibromatosis type 2. J Neurosurg. 2003;99:480-483.
7. Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery. 1996;38: 880-885.
8. Baser ME, Friedman JM, Aeschliman D, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet. 2002;71: 715-723.
9. Slattery WH, Fisher LM, Iqbal Z, et al. Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol. 2004;25:811-817.
10. Samii M, Matthies C, Tatagiba M. Management of vestibular schwannomas (acoustic neuromas): Auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery. 1997;40:696-705.
11. Mathieu D, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: An analysis of tumor control complications and hearing preservation rates. Neurosurgery. 2007;60:460-468.
12. Brackmann DE, Fayad JN, Slattery WH, et al. Early proactive management of vestibular schwannomas in neurofibromatosis type 2. Neurosurgery. 2001;49:274-280.
13. Goutagny S, Kalamarides M. Meningiomas and neurofibromatosis. J Neurooncol. 2010;99(3):341-347.
14. Goutagny S, Yang HW, Zucman-Rossi J, et al. Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res. 2010; 16:4155-4164.
15. Hsu DW, Efird JT, Hedley-Whyte ET. Progesterone and estrogen receptors in meningiomas: Prognostic considerations. J Neurosurg. 1997;86(1):113-120.
16. Lamszus K, Vahldiek F, Mautner VF, et al. Allelic losses in neurofibromatosis 2-associated meningiomas. J Neuropathol Exp Neurol. 2000;59:504-512.
17. Antinheimo J, Haapasalo H, Halite M, et al. Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. J Neurosurg. 1997;87:610-614.
18. Perry A, Giannini C, Raghavan R, et al. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: A clinicopathologic study of 53 cases. J Neuropathol Exp Neurol. 2001;60:994-1003.
19. Blakeley JO, Evans DG, Adler J, et al. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A. 2011. Published online ahead of print December 2, 2011. doi: 10.1002/ajmg.a.34359.
20. Kondziolka D, Madhok R, Lunsford LD, et al. Stereotactic radiosurgery for convexity meningiomas. J Neurosurg. 2009;111(3):458-463.
21. Wentworth S, Pinn M, Bourland JD, et al. Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. Int J Radiat Oncol Biol Phys. 2009;73(1):208-213.
22. Kalamarides M, Stemmer-Rachamimov AO, Niwa-Kawakita M, et al. Identification of a progenitor cell of origin capable of generating diverse meningioma histologic subtypes. Oncogene. 2011;30(20):2333-2344.
23. Sughrue ME, Rutkowski MJ, Aranda D, Barani IJ, McDermott MW, Parsa AT. Treatment decision making based on the published natural history and growth rate of small meningiomas. J Neurosurg. 2010;113(5):1036-1042.
24. Lee JH, Sade B, Choi E, et al. Meningothelioma as the predominant histological subtype of midline skull base and spinal meningioma. J Neurosurg. 2006;105:60-64.
25. Kros J, de Greve K, van Tilborg A, et al. NF2 status of meningiomas is associated with tumor localization and histology. J Pathol. 2001;194:367-372.
26. Couly GF, Douarin NML. Mapping of the early neural primordium in quail-chick chimeras. II. The prosencephalic neural plate and neural folds: Implications for the genesis of cephalic human congenital abnormalities. Dev Biol. 1987;120:198-214.
27. Evans DG, Kalamarides M, Hunter-Schaedle K, et al. Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res. 2009;15:5032-5039.